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Zurich, Switzerland
rich thrombi to conventional fibrinolytic therapy. A highly effec-
tive approach is inhibition of the final platelet aggregation path-
way, by blocking the activated platelet receptor glycoprotein
(GP) IIb/IIIa. Kong and associates1 have surveyed 16 clinical tri-
als using a variety of inhibitors of GP IIa/IIIa and reported an
overall 35% reduction in risk of 30-day mortality and myocardial
infarction. However, other authors have reported increased hem-
orrhage in patients receiving the synthetic inhibitors eptifibatide2
and abciximab.3
Tirofiban (Aggrestat; Merck & Co, Inc, Whitehouse Station,
NJ) is a nonpeptide tyrosine derivative that acts as a reversible,
selective antagonist of GP IIb/IIIa. It induces more than 90%
inhibition of platelet aggregation after a 30-minute infusion, with
platelet function returning to near-baseline levels by 4 to 8 hours
after the end of infusion. The use of tirofiban together with
heparin in the treatment of acute coronary syndrome has given
particularly promising results. Thus, in the PRISM trial,4 patients
who received tirofiban plus heparin showed a 33% risk reduction
in the composite end point and a 36% risk reduction in refracto-
Interest in the development of new strategies to preventplatelet aggregation in acute coronary syndrome has beenstirred by a growing appreciation of the role of plateletaggregation in thrombosis and of the resistance of platelet-
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ry ischemia at 48 hours. In the RESTORE study,5 the tirofiban
group showed a 38% risk reduction in composite end point and a
39% risk reduction in myocardial infarction alone at 48 hours. In
both studies the incidence of major bleeding was higher among
patients in the tirofiban group, but the difference was not statisti-
cally significant. Because of concern over the potential disrup-
tion of blood coagulation during surgery after the use of
inhibitors of platelet aggregation, current recommendations
require tirofiban treatment to be halted at least 8 hours before the
start of a surgical intervention. Clearly, this may put at risk some
patients who have received tirofiban and who urgently require
surgical intervention.
We have retrospectively compared the risk of hemorrhage in
patients whose tirofiban infusion was stopped at different times
preceding the start of surgery. Between December 1998 and
April 2000, 40 patients who were already being treated with
tirofiban in the Triemli City Hospital, Zurich, also required
either emergency surgical procedures or operations that had to
be performed earlier than planned. Seventeen of these 40
patients (Early Stop) had their tirofiban infusion stopped more
than 8 hours previously (mean = 40.5 ± 39.1 hours), whereas in
the other 23 (Late Stop) the tirofiban infusion was stopped less
than 8 hours (mean = 3.4 ± 1.8 hours) before surgery. The high
incidence of the need for preoperative intravenous heparin
(Early Stop, 36%, Late Stop, 100%, P = .01) and an intra-aortic
balloon pump (Early Stop, 29%, Late Stop, 69%, P = .01) in
these patients demonstrates their clinical instability and the cor-
responding risk involved in delaying surgical intervention. On
assessment before surgery, the two groups were comparable for
the measured coagulation parameters (Table 1).
In both groups, coagulation parameters were again evaluat-
ed at the end of the operation (Table 1). The amount of blood
drained in the first 24 postoperative hours and the transfusion
volumes (of erythrocytes, thrombocyte concentrate, and fresh
frozen plasma) required during postoperative hospitalization
were also recorded (Table 2). The results showed no clinically
or statistically significant intergroup differences in the postop-
erative coagulation parameters, nor was any relationship
observed between the volume of blood lost in the first 24 hours
and the interval between the end of tirofiban infusion and
surgery. All patients were monitored for perioperative myocar-
dial infarction, including analysis of the electrocardiogram, cre-
atine kinase, troponin, and myoglobin. Only 1 patient had a
postoperative myocardial infarction, and this patient was in the
Late Stop group. 
The results of this study are of clinical significance in that
they indicate that the GP IIb/IIIa inhibitor tirofiban can be used
at any point before heart surgery without increasing the risk of
hemorrhage. Anti-ischemic therapy can therefore be offered
without interruption to patients with acute coronary syndrome
scheduled for surgery, avoiding the need for potentially critical
delays to surgical intervention.
TABLE 1. Preoperative and postoperative coagulation parameters
Early Stop (n = 17) Late Stop (n = 23) P value
Postoperative coagulation parameters
Thrombin time (s) 22 ± 14 21 ± 11 .4
Quick (%) 77 ± 18 77 ± 10 .3
ACT (s) 147 ± 26 137 ± 22 .4
Fibrinogen (mg/dL) 312 ± 84 283 ± 89 .8
Platelets (¥10 9/L) 109 ± 34 114 ± 30 .5
Preoperative coagulation parameters
Quick (%) 96 ± 14 99 ± 11 .44
ACT (s) 184 ± 33 186 ± 33 .99
Fibrinogen (mg/dL) 402 ± 86 392 ± 79 .12
Platelets (×10 9/L) 215 ± 73 251 ± 71 .85
Values are mean ± standard deviation. ACT, Activated clotting time.
TABLE 2. Postoperative bleeding and transfusion requirements
Early Stop (n = 17) Late Stop (n = 23) P value
Bleeding (mL/24 h) 923 ± 734 (median = 745) 845 ± 481 (median = 700) .06
Transfusions
Erythrocytes (U) 5.5 ± 3 3 ± 2 .01
Platelets (IU) 2.6 ± 5.4 2.5 ± 4.4 .92
FFP (U) 2.3 ± 2.7 0.9 ± 1.3 .08
Except where stated, values are mean ± standard deviation. FFP, Fresh frozen plasma. 
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